Liveworld

August 15, 2011 looms as the date when disease-state and over-the-counter (OTC) pharma brands will no longer be able to prevent fans from commenting on their Facebook Pages. This also means an obligation to watch for and report all adverse events (AE) on the Page.
So how much AE content should pharma brands realistically expect?
To find out, LiveWorld analyzed fan behavior on 5 existing client pharma Facebook Pages already allowing comments. We looked at more than 9,000 comments over a three-month period on these Pages, which range in size from under 50 fans on the low end (for a brand-new Page) to more than 2 million fans on the high end.
Here are our key findings and moderation recommendations:
* There was no significant flood of adverse events or other critical issues on the Pages. Less than 2 % of fan posts and comments across all pages were reports of Adverse Events.
* There was no correlation between number of adverse events and either the number of brand posts/week or the total number of fans. AE content was consistently less than 2 %.
* Advanced training of moderators (5 hours +) ensures understanding of company/brand and FDA rules, and human review of Facebook comment is the best practice for compliance.

Read full case study

For more data and details from our research, check out the full case study, which is embedded as a public document below, and on Slideshare.

LiveWorld can and does support pharma companies and other brands with their Facebook moderation needs, including the reporting of adverse events to the FDA. If you have questions about our services, please call us at 1-800-301-9507.